Free Trial
→ Last note from me on this (From The Cycle Code) (Ad)tc pixel
NASDAQ:AKBA

Akebia Therapeutics Q3 2026 Earnings Date & Estimates

Akebia Therapeutics logo
$0.71 -0.04 (-4.81%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$0.70 0.00 (-0.21%)
As of 10/30/2026 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Akebia Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Akebia Therapeutics in Q3 2026

Akebia Therapeutics is expected to post earnings of -$0.0360 per share on revenue of $46.94 million. Akebia Therapeutics last reported on August 5, 2026, posting -$0.02 per share and beating the -$0.0420 consensus estimate. Akebia Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0360
Expected Revenue
$46.94 million

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.02 (Beat by +$0.0220)
Last Quarter Revenue
$49.13 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Akebia Therapeutics Q3 2026 Earnings FAQ

Akebia Therapeutics (NASDAQ:AKBA) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Akebia Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Akebia Therapeutics to post earnings of -$0.0360 per share for Q3 2026.

The consensus revenue estimate for Akebia Therapeutics is $46.94 million for Q3 2026.

Akebia Therapeutics Earnings Headlines

Akebia Therapeutics (AKBA) Expected to Release Earnings on Thursday
October 31 at 2:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31169238
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
October 29 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391209/37519/en/akebia-therapeutics-to-report-third-quarter-2026-financial-results-and-discuss-recent-business-highlights.html
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
October 31 at 1:00 AM  |  Monument Traders Alliance (Ad)
Keros Therapeutics (NASDAQ:KROS) & Akebia Therapeutics (NASDAQ:AKBA) Financial Survey
October 28 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31164155
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at ...
October 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/u-s-renal-care-presents-analysis-of-voice-trial-demonstrating-favorable-safety-outcomes-for-patients-treated-with-vadadustat-versus-an-esa-during-a-late-breaking-session-at-american-society-of-1036665567
Akebia Therapeutics and U.S. Renal Care Present Positive VOICE Trial Data for Vafseo at ASN Kidney Week 2026
October 26, 2026  |  quiverquant.comQ
See More Akebia Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akebia Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akebia Therapeutics and other key companies, straight to your email.

About Akebia Therapeutics

Akebia Therapeutics (NASDAQ:AKBA) is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company’s primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.

Akebia’s key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body’s natural production of erythropoietin and support red blood cell formation. Vafseo has been approved in the United States for the treatment of anemia due to CKD in adults on dialysis and is also approved in certain international markets. Akebia also markets Auryxia (ferric citrate), which is used to control serum phosphorus levels in adults with CKD on dialysis and to treat iron deficiency anemia in certain adults with CKD who are not on dialysis.

The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Akebia commercializes its products in the United States and has worked with international partners to support the availability of vadadustat in markets outside the country. John P. Butler serves as Akebia’s president and chief executive officer.

View Akebia Therapeutics Profile
Earnings Tools